Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Subtenon triamcinolone acetonide injection to prevent rejection post penetrating keratoplasty

Poster Details

First Author: J.Kim SOUTH KOREA

Co Author(s):    J. Hong   A. Yoo   M. Kim   H. Tchah           

Abstract Details


To investigate the effects of postoperative subtenon triamcinolone acetonide (StTA) injection on the graft rejection and failure after penetrating keratoplasty.


University of Ulsan College of Medicine, Asan Medical Center, Korea


Between 2009 and 2012, 119 eyes out of 89 patients who underwent penetrating keratoplasty (PK) by one surgeon were included. 102 eyes received StTA injection every three months after PK (StTA group) and 17 eyes did not receive StTA (control group). The follow-up visits were at one, 3, 6, and 12 months. The visual acuity, intraocular pressure, refraction were checked at each visits. The slit lamp biomicrocopy was used to decide the presence of graft rejection. The Kaplan-Meier survival analysis and binary multivariate logistic regression analyses were performed to compare the incidence of graft rejection between two groups.


The Kaplan-Meier survival analysis showed that the StTA group showed less graft rejection than the control group (p=0.02). The binary multivariate logistic regression analyses revealed that th pre-PK glaucoma surgical history was a risk factor for graft rejection but post-PK StTA injection and aggressive IOP control were a protective factor (all p values were less than 0.05). However, there were minor complications including temporary IOP elevation and epithelial defect. The StTA injection after PK did not significantly increase postoperative IOP (p value was more than 0.05).


Post-PK StTA injection could be helpful to prevent graft rejection in spite of minor complications including temporary IOP elevation and epithelial defect.

Financial Disclosure:


Back to Poster listing